Evidence map›Paper›PMID 28411178›Full record

SynthesisHuman pathology2017

MicroRNA expression profiling of Xp11 renal cell carcinoma.

Luigi Marchionni, Masamichi Hayashi, Elisa Guida, Akira Ooki, Enrico Munari, Fayez J Jabboure, Wikum Dinalankara, Ali Raza, George J Netto, Mohammad O Hoque and 1 more

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 3 countries.

Luigi MarchionniDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Center for Computational Genomics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: marchion@jhu.edu.
Masamichi HayashiDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Elisa GuidaDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Akira OokiDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Enrico MunariDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Pathology, Sacro Cuore Hospital Negrar, Verona 37024, Italy.
Fayez J JabboureDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wikum DinalankaraDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ali RazaDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
George J NettoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama School of Medicine, Birmingham, AL 35233, USA.
Mohammad O HoqueDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Pedram ArganiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: pargani@jhmi.edu.
Johns Hopkins University · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational LearningR01CA200859 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARCHIONNI, LUIGI · 2016 to 2020
$1.9M
NCATS NIH HHS UL1 TR001079NCI NIH HHS R01 CA200859
6 · The paper itself

Abstract

Renal cell carcinomas (RCCs) with Xp11 translocation (Xp11 RCC) constitute a distinctive molecular subtype characterized by chromosomal translocations involving the Xp11.2 locus, resulting in gene fusions between the TFE3 transcription factor with a second gene (usually ASPSCR1, PRCC, NONO, or SFPQ). RCCs with Xp11 translocations comprise up to 1% to 4% of adult cases, frequently displaying papillary architecture with epithelioid clear cells. To better understand the biology of this molecularly distinct tumor subtype, we analyze the microRNA (miRNA) expression profiles of Xp11 RCC compared with normal renal parenchyma using microarray and quantitative reverse-transcription polymerase chain reaction. We further compare Xp11 RCC with other RCC histologic subtypes using publically available data sets, identifying common and distinctive miRNA signatures along with the associated signaling pathways and biological processes. Overall, Xp11 RCC more closely resembles clear cell rather than papillary RCC. Furthermore, among the most differentially expressed miRNAs specific for Xp11 RCC, we identify miR-148a-3p, miR-221-3p, miR-185-5p, miR-196b-5p, and miR-642a-5p to be up-regulated, whereas miR-133b and miR-658 were down-regulated. Finally, Xp11 RCC is most strongly associated with miRNA expression profiles modulating DNA damage responses, cell cycle progression and apoptosis, and the Hedgehog signaling pathway. In summary, we describe here for the first time the miRNA expression profiles of a molecularly distinct type of renal cancer associated with Xp11.2 translocations involving the TFE3 gene. Our results might help understanding the molecular underpinning of Xp11 RCC, assisting in developing targeted treatments for this disease.

Indexed as

Chromosomes, Human, XTranslocation, GeneticAdolescentAdultBiomarkers, TumorCarcinoma, Renal CellChildChild, PreschoolComputational BiologyDatabases, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansKidney NeoplasmsBiomarkers, TumorMicroRNAsAnalysis of Functional Annotationgene regulationmicroRNA expression profilingRenal cell carcinomaTFE3 gene fusionXp11 translocation

Identifiers

PMID28411178
PMCPMC5628161
OpenAlexW2605961828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.